ARTICLE | Analyst Picks & Changes
Analyst picks & changes
May 16, 1994 7:00 AM UTC
S.G. Warburg analyst Kevin Wilson downgraded Genentech Inc. to "add" from "buy" on the basis of valuation. Wilson said the South San Francisco company's fundamentals remain "sterling" and the company still is the highest-quality name in biotech. He maintained his 12-month target of $54. ...